Ethanol (EH)

La catena delle opzioni mostra i dati chiave delle opzioni azionarie di EHang Holdings a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per EHang Holdings..

EHang Holdings (NASDAQ:EH) Azioni, Catena delle Opzioni

EHang Holdings

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

EHang Holdings Ltd

ISH HYCB UCITS ETF

Enhabit Inc

Encompass Health Corporation Common Stock

Encompass Health Corp

Eshallgo Inc

STAR ENTMT GROUP LTD ORD by Star Entertainment Group Limited

The Star Entertainment Group Ltd

Western Asset Global High Income Fund Inc Common Stock

Western Asset Global High Inc Fd Inc

EDINBURGH INVST TR by Edinburgh Investment Trust

Even Herd Long Short ETF

goeasy Ltd

Ehouse Global Inc

EAGLE HOSPTLTY PPT/TR PFD by Eagle Hospitality Properties Trust Inc.

Eagle Hospitality Properties Trust Inc

eHealth Inc

Ehave Inc

EHYDROGEN SOLUTIONS INC by Ehydrogen Solutions, Inc.

Ratings for MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $259.75, a high estimate of $325.00, and a low estimate of $185.00. Witnessing a positive shift, the current average has risen by 8.0% from the previous average price target of $240.50.
<img src="https://www.benzinga.com/files/images/story/2024/1730984418_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive MarketAxess Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$314.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$268.00</td>
<td>$237.00</td>
</tr>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$325.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$185.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$233.00</td>
<td>$204.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$223.00</td>
<td>$218.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to MarketAxess Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into MarketAxess Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on MarketAxess Holdings analyst ratings.</a>
<h2>Delving into MarketAxess Holdings's Background</h2>
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Borse Group in 2020 adding to its product offerings.
<h3>MarketAxess Holdings's Economic Impact: An Analysis</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: MarketAxess Holdings displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 9.91%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MarketAxess Holdings's net margin is impressive, surpassing industry averages. With a net margin of 32.85%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): MarketAxess Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 4.91%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): MarketAxess Holdings's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: MarketAxess Holdings's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MKTX

Cracking The Code: Understanding Analyst Reviews For MarketAxess Holdings

B of A Securities analyst Ken Hoexter upgrades Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) from Underperform to Buy and raises the price target from $27 to $34.

News

Upgrades

Price Target

SNDR

B of A Securities Upgrades Schneider National to Buy, Raises Price Target to $34

Needham analyst Mayank Tandon maintains Q2 Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NYSE">QTWO</a>) with a Buy and raises the price target from $90 to $120.

QTWO

Needham Maintains Buy on Q2 Holdings, Raises Price Target to $120

Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) reported quarterly losses of $(1.24) per share which missed the analyst consensus estimate of $(1.08) by 14.81 percent. This is a 22.5 percent increase over losses of $(1.60) per share from the same period last year.

Earnings

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Therapeutics Q3 2024 GAAP EPS $(1.24) Misses $(1.08) Estimate

Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.88) by 34.09 percent.

Earnings Beats

SAVA

Cassava Sciences Q3 2024 GAAP EPS $(0.58) Beats $(0.88) Estimate

Needham analyst Bernie McTernan reiterates Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and maintains $16 price target.

Reiteration

SRAD

Needham Reiterates Buy on Sportradar Gr, Maintains $16 Price Target

Burford Capital Limited, the leading global finance and asset management firm focused on law, has noted inaccurate media reporting and subsequent market reaction to an expected court filing last night by the U.S. Department of Justice ("DOJ") in the Petersen and Eton Park matters. The filing in the U.S. District Court for the Southern District of New York restates DOJ's position on a narrow question of law in relation to enforcement of judgments. The filing pertains to one motion filed in the Petersen and Eton Park matters as part of the overall, ongoing effort to enforce the judgment against the Argentine Republic. The filing does not reflect DOJ's taking any broader position on the overall case or the enforcement campaign; indeed, DOJ has previously taken the position that pursuing Argentina in the US courts for its breach of contract in this matter was appropriate, and DOJ has not made any filing at all on the pending appeal (and the time to do so has passed). In its filing, DOJ took the view that Argentina could not be required by a U.S. court to move property presently located in Argentina into the United States so it could there be attached for creditors under New York law, which is an unsettled legal issue. The DOJ view is not binding on the court and further briefing and proceedings will ensue. The Company will provide a further update on the Petersen and Eton Park matters during today's earnings call.

Legal

Burford Capital Highlights Inaccurate Media Reports On DOJ Court Filing In Petersen, Eton Park Cases; Filing Focuses on Legal Enforcement Issue, Not Broader Case; DOJ States Argentina's Property Cannot Be Moved To U.S. For Creditor Attachment; The DOJ View Is Not Binding On The Court And Further Briefing And Proceedings Will Ensue

Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.84) by 7.14 percent.

Guidance

TRML

Tourmaline Bio Q3 2024 GAAP EPS $(0.78) Beats $(0.84) Estimate, Cash, Cash Equivalents And Investments Of $314.4M, Providing Cash Runway Into 2027

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58933b2043eaaa0001698f4c/eric-coldwell">Baird analyst Eric Coldwell</a> upgraded the rating for McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) from Neutral to Outperform and raised the price target from $531 to $688. McKesson shares closed at $549.31 on Wednesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Ric Prentiss upgraded United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) from Market Perform to Outperform and announced a price target of $86. United States Cellular shares closed at $65.15 on Wednesday. <a href="https://www.benzinga.com/quote/USM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e00b6e13513fb0001f03e9b/kristen-kluska">Cantor Fitzgerald analyst Kristen Kluska</a> upgraded the rating for Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) from Neutral to Overweight and boosted the price target from $152 to $167. Sarepta Therapeutics shares closed at $127.97 on Wednesday. <a href="https://www.benzinga.com/quote/SRPT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Alexei Gogolev upgraded Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) from Neutral to Overweight and raised the price target from $23 to $33. Clearwater Analytics shares closed at $28.58 on Wednesday. <a href="https://www.benzinga.com/quote/CWAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Steven Cahall upgraded the rating for Sinclair, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBGI#NASDAQ">SBGI</a>) from Underweight to Equal-Weight and increased the price target from $13 to $19. Sinclair shares closed at $17.41 on Wednesday. <a href="https://www.benzinga.com/quote/SBGI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying MCK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png" alt="" class="wp-image-635130" style="width:629px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07075449/image-75.png 1216w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom"> </a>
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CWAN

SBGI

SRPT

This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Keefe, Bruyette &amp; Woods analyst Paul Johnson upgrades TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) from Underperform to Market Perform and lowers the price target from $8 to $7.5.

TPVG

Keefe, Bruyette & Woods Upgrades TriplePoint Venture Gwth to Market Perform, Lowers Price Target to $7.5

Biotech

Health Care

General

CARM

CARISMA Therapeutics' Q3 Cash And Cash Equivalents Of $26.9M Expected To Fund The Company Into The Third Quarter Of 2025

Stephens &amp; Co. analyst Jim Salera reiterates Papa John's International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PZZA#NASDAQ">PZZA</a>) with a Overweight and maintains $62 price target.

PZZA

Stephens & Co. Reiterates Overweight on Papa John's International, Maintains $62 Price Target

WIIM

KVYO

Klaviyo shares are trading lower. The company reported Q3 financial results.

CARISMA Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.24) by 29.17 percent. The company reported quarterly sales of $3.38 million which missed the analyst consensus estimate of $5.47 million by 38.08 percent. This is a 11.55 percent decrease over sales of $3.83 million the same period last year.

CARISMA Therapeutics Q3 2024 GAAP EPS $(0.31) Misses $(0.24) Estimate, Sales $3.38M Miss $5.47M Estimate

MRNA

Moderna shares are trading higher after the company reported better-than-expected Q3 sales results.

Burford Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUR#NYSE">BUR</a>) reported quarterly earnings of $0.61 per share which missed the analyst consensus estimate of $0.92 by 33.7 percent. The company reported quarterly sales of $249.114 million which missed the analyst consensus estimate of $393.893 million by 36.76 percent. This is a 32.47 percent decrease over sales of $368.873 million the same period last year.

Earnings Misses

Burford Capital Q3 2024 GAAP EPS $0.61 Misses $0.92 Estimate, Sales $249.114M Miss $393.893M Estimate

Chicago Atlantic Real Estate Finance, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) <a href="https://www.globenewswire.com/en/news-release/2024/11/07/2976505/0/en/Chicago-Atlantic-Real-Estate-Finance-Announces-Third-Quarter-2024-Financial-Results.html">announced</a> strong third-quarter results for 2024. The company, a commercial mortgage real estate investment trust (REIT) specializing in cannabis-related assets, reported significant net income growth and expanding portfolio performance, underpinned by disciplined loan management.
<h3 class="wp-block-heading">Key Financial Highlights for Q3 2024</h3>
<ul>
<li>Net Interest Income:&nbsp;$14.5 million, up from $13.2 million in Q2 2024 and a 9.1% increase from Q3 2023.</li>
<li>Net Income:&nbsp;$11.2 million, or $0.56 per share, a 21.7% sequential increase and a 19% year-over-year increase.</li>
<li>Distributable Earnings:&nbsp;$11.2 million, or $0.56 per share, reflecting a 12% quarterly increase and a 15% year-over-year rise.</li>
<li>Book Value:&nbsp;$15.05 per share, up slightly from $14.92 in <a href="https://www.benzinga.com/markets/cannabis/24/08/40228072/cannabis-reit-chicago-atlantic-nets-9-2m-in-strong-q2-citing-regulatory-tailwinds">Q2 2024</a>, showing growth in shareholder equity.</li>
</ul>
<h3 class="wp-block-heading">Portfolio And Investment Activity</h3>
As of September 30, 2024, Chicago Atlantic's portfolio included $362.3 million in <a href="https://www.benzinga.com/markets/cannabis/24/10/41496393/chicago-atlantic-secures-bbb-rating-and-50m-loan-to-enhance-liquidity-in-cannabis-lending">loan principal </a>across 29 companies, with a real estate collateral coverage of 1.2x, slightly down from 1.3x in June. 
The company originated $32.7 million in gross loans during Q3, including $24 million to new borrowers and $8.7 million to existing ones, with a weighted average yield to maturity of 18.3%. 
After the quarter's close, Chicago Atlantic funded an additional $36.5 million, including a $25 million credit facility with an Illinois operator.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
"We have managed our portfolio and its maturities very well throughout 2024 with extensions, modifications, and refinancings, while improving credit quality and loan coverage,&#8221; stated co-CEO <a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">Peter Sack</a>. &#8220;A strong pipeline in both existing and new states with adult-use legislation keeps us well-positioned for the balance of the year and into 2025."
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41237545/exclusive-weed-companies-will-be-treated-like-normal-businesses-once-this-tax-provision-goes-awa">EXCLUSIVE: Weed Companies Will Be Treated Like Normal Businesses Once This Tax Provision Goes Away, Experts Say</a>
<h3 class="wp-block-heading">Capital And Liquidity Management</h3>
During Q3, Chicago Atlantic increased its secured revolving credit facility to $110 million, with a drawdown of $54 million as of quarter-end, resulting in a leverage ratio of 18%. 
In October, the company secured a $50 million unsecured term loan with a fixed interest rate of 9.0% and received an investment-grade BBB+ rating from Egan-Jones. This loan strengthens Chicago Atlantic's liquidity, leaving $94.5 million available under the facility and approximately $80 million in total liquidity as of early November.
The company also paid a quarterly dividend of $0.47 per share on October 15, reflecting its steady return to shareholders amid robust performance.
<h3 class="wp-block-heading">REFI Stock Price Action</h3>
REFI shares closed Wednesday at $15.58 per share gaining +0.33 during the trading session, which represents a 2.16% increase.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40607517/delivering-returns-as-the-cannabis-market-tanks-what-wall-st-wont-tell-you-about-ch">Delivering Returns As The Cannabis Market Tanks: What Wall St Won&#8217;t Tell You About Chicago Atlantic Real Estate&#8217;s Growth</a></li>
</ul>
COVER: AI Generated Image

Cannabis

REFI

Chicago Atlantic Real Estate Net Income Increases 19% YoY, Expands Cannabis Loan Portfolio

Vertical Research upgrades Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) from Hold to Buy and announces $109 price target.

Vertical Research Upgrades Intl Flavors & Fragrances to Buy, Announces $109 Price Target

HC Wainwright &amp; Co. analyst Kevin Dede maintains Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy and raises the price target from $15 to $17.

Core Scientific, Inc. - Class A Common Stock

CORZ

HC Wainwright & Co. Maintains Buy on Core Scientific, Raises Price Target to $17

United States Cellular shares are trading higher after the company announced an agreement with AT&T to sell a portion of its retained spectrum licenses for $1.018 billion.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
EHang Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/eh-stock-quote/">EH</a>) just reported results for the second quarter of 2024.<ul><li>EHang Holdings reported earnings per share of 0.2 cent. This was above the analyst estimate for EPS of -12 cents.</li><li>The company reported revenue of $14.04 million.</li><li>This was better than the analyst estimate for revenue of $12.52 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/eh-stock-earnings-ehang-holdings-for-q2-of-2024/">EH Stock Earnings: EHang Holdings Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

EH Stock Earnings: EHang Holdings Beats EPS, Beats Revenue for Q2 2024

EHang: Explosive Growth Forecast (Rating Upgrade)

Warning: EH is at high risk of performing badly

Bearish flow noted in EHang (EH) Holdings Ltd with 2,720 puts trading, or 2x expected. Most active are 11/1 weekly 16 puts and Nov-24 18 puts, with...

EHang Holdings Ltd put volume heavy and directionally bearish

Bearish flow noted in EHang (EH) Holdings Ltd with 8,085 puts trading, or 3x expected. Most active are 11/22 weekly 16 puts and Nov-24 21 calls, wi...

Screenshot 2024-05-30 at 6.26.23 PM

Emerging Markets

Movers & Shakers

ACHR

HOVR

JOBY

LILM

New Horizon Aircraft (NASDAQ: HOVR) Announces Key Technical Updates On Development Of eVTOL Prototype

Press Releases

EHang's Pilotless eVTOL Air Operator Certificate Application Accepted by CAAC

First Batch of EHang's EH216-S Delivered to Xishan Tourism and Completed Debut Passenger-Carrying Flights in Taiyuan

EHang to Report Second Quarter 2024 Unaudited Financial Results on Thursday, August 22, 2024

EHang Reports Second Quarter 2024 Unaudited Financial Results

EHang Strongly Refutes False Allegations, Clarifies Misinformation Causing Stock Volatility

Brazil and China Strengthen Cooperation on Civil Aviation Airworthiness: EHang's EH216-S Pilotless eVTOL Obtains Experimental Flight Authorization Certificate from Brazil's National Civil Aviation Agency

EH216-S Pilotless eVTOL Completes First Flight in Brazil

Commercial Drone Industry Has Expanded Significantly as Billion Dollar Market is Awarding Lucrative Opportunities for Manufacturers

EHang and Civil Aviation Flight University of China Form Strategic Partnership to Jointly Develop Professional Talents and Vocational Training for Large Civil Unmanned Aerial Vehicles

Comments

EHang Holdings

EHang Holdings (EH) Opzioni

EHang Holdings (NASDAQ:EH) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO